Stathmin: A "Relay Protein" in the Development of Prostate Cancer and a Potential Target for Anticancer Therapy
Annual summary rept. 15 Oct 2005-14 Oct 2006
VANDERBILT UNIV MEDICAL CENTER NASHVILLE TN
Pagination or Media Count:
The long term goal of this work is to determine weather stathmin can be targeted as an effective therapy in the clinic against prostate cancer. The central hypothesisof this proposal is that overexpression of stathmin promotes prostate cancer development and blocking stathmin expression sensitizes prostate cancer cells to anticancer therapies such as Taxotere and Erbitux. The purpose of this work is to i correlate stathmin overexpression with progression of prostate cancer, ii determine the signaling pathways activated through selective phosphorylation of stathmin and weather inactivation of these pathways promotes sensitization to treatment with Taxotere or Erbitux and iii examine the effects of stathmin expression on tumor development and the outcomes of Taxotere, Erbitux on blocking tumorigenesis in tissue recombination and transgenic mouse models. The rationaleis to develop combinatorial treatment strategies for better clinical management of prostate cancer patients. Targeting stathmin in prostate cancer can potentially sensitize patients to treatment with Taxotere or Erbitux. Since the agents selected have already been used in the clinic, successful outcomes in the animal models can result in rapid clinical trials.
- Medicine and Medical Research